cAMP-elevating agents suppress dendritic cell function

Journal of Leukocyte Biology

Volumn 70, Issue 6, 2001, Pages 903-910

  Kambayashi, Taku ^a   Wallin, Robert P A ^a   Ljunggren, Hans Gustaf ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antigen presentation; Cytokinesd; Lipopolysaccharide; Rug inhibitors

Indexed keywords

8 BROMO CYCLIC AMP; CYCLIC AMP; INTERLEUKIN 10; ISOBUTYLMETHYLXANTHINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PROSTAGLANDIN E2; QUAZINONE; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFECT; DRUG INDICATION; DRUG SCREENING; IMMUNOPHARMACOLOGY; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0035216666     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Capture and processing of exogenous antigens for presentation on MHC molecules
2. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products
3. Inflammatory, stimuli induce accumulation of MHC class II complexes on dendritic cells
4. Developmental regulation of MHC class II transport in mouse dendritic cells
5. Bacteria-induced neobiosynthesis, stabilization, and surface expression of functional class 1 molecules in mouse dendritic cells
6. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo
7. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites
8. Distinct patterns and kinetics of chemokine production regulate dendritic cell function
9. Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2
10. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells
11. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12
12. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor betal and beta2 chain expression
13. Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: Synergistic activation of interleukin 12 production
14. Differential deactivation of human dendritic cells by endotoxin desensitization: Role of tumor necrosis factor-alpha and prostaglandin E2
15. Prostaglandin E2 is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer
16. Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein
17. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases
18. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages
19. Characterization of the phosphodiesterase (PDE) pattern of in vitro-generated human dendritic cells (DC) and the influence of PDE inhibitors on DC function
20. Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo
21. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor
22. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis
23. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram
24. Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram
25. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors
26. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects
27. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents